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Abstract
Background: While a link between abacavir and CVD risk is suggested, 
an association between abacavir and hypertension remains unclear.
Purpose: To validate the use of claims database in research of 
HIV-infected individuals, and evaluate the incidence and risk of 
hypertension induced by abacavir among HIV–infected individuals.
Materials and Methods: We constructed a nationwide cohort of 
HIV-infected individuals using the Health Insurance Review and 
Assessment Service (HIRA) database of the National Health Insurance 
System (NHIS) from the period of 2007-2016, and compared the 
numbers of individuals with the official reports of the government. From 
6093 HIV-infected individuals on their initial ART, 1,234 who had used 
abacavir or non-abacavir ART without switch were were selected after 
propensity score matching. The use of ART was treated as a 
time-varying covariate measured as a daily unit. Incidence rate of 
hypertension was calculated, and Cox proportional hazard models were 
used to estimate adjusted hazard ratios (HRs) with their 95% confidence 
interval (CI) of incident hypertension overall and among subgroups. 
Results: The cohort from HIRA database showed similar numbers of 
individuals with the ones detected by the government. Among the total 
6,093 HIV-infected individuals, incidence rates of hypertension were 4.6 
and 3.6 per 100 person-years for abacavir and non-abacavir ART users, 
respectively. The population attributable fraction of abacavir use on 
hypertension was 12%. Among the matched 1,234 subjects, abacavir 
exposure elevated the risk of hypertension among overall study 
population. However, those aged over 30’s, with psychiatric disorders, 
and diagnosed after the year 2013 were at higher risk of hypertension 
induced by abacavir.
Conclusion: We constructed a database that can be used as a source of 
HIV epidemiology studies in the future. Those diagnosed after the year 
2013 may warrant additional concern for hypertension in patients treated 
with abacavir.
Keywords : hypertension; abacavir; HIV; antiretroviral therapy;
epidemiology
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1. Introduction
  1.1 Background
Hypertension is the most important risk factor for a variety of 
premature cardiovascular diseases (CVDs). Research has indicated that HIV 
infection increases blood pressure1 and that traditional CVD risk factors, such 
as hypertension, contributes additional risk, independent of and in addition to 
that contributed by HIV infection.2 While exposure to antiretroviral treatment 
(ART) has been reported to increase blood pressure with an odds ratio of 
1.68, there is scarce data on whether a specific ART increases the risk.3
Abacavir, a first-line ART agent, has been on the market since 1998. 
In 2008, the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) 
study reported an association between recent abacavir exposure and an 
increased rate of myocardial infarction.4 Nevertheless, studies have yet to 
confirm how and whether or not abacavir elevates CVD risk5-8: it is necessary 
to confirm the long-term safety of abacavir use because, ultimately, people 
living with HIV (PLWH) will be on ART for decades. While one study has 
shown that, among several ARTs, only patients using abacavir exhibit a 
slightly higher risk of hypertension,9 no study has conducted a survival 
analysis of the hypertension risk associated with abacavir use in initial ART 
among PLWH over an extended follow-up duration.
While the database of nationwide HIV-infected individuals is managed 
only by the government, Korea Center for Disease Control and Prevention 
(KCDC), there is no history of using the database as a source of any 
epidemiological studies. However, there is a fully covered health insurance of 
all national population in South Korea, of which has many potential is its use 
in epidemiological studies. Since it is particularly difficult to recruit 
HIV-infected individuals regarding prejudice among the infected, creating a 
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database for the source of HIV researches is more than necessary.
  1.2 Objectives
In order to assess the possibility and validity of using claims database 
as a source for HIV epidemiology studies, we constructed a nationwide cohort 
(from 2008 to 2016) of HIV-infected individuals using the HIRA database 
from 2007-2016. Also, In order to evaluate the risk of hypertension with 
abacavir use in comparison to non-abacavir ART, we analyzed the cohort 
considering drug exposure as a time-varying covariate measured on a daily 
basis.
2. Materials and Methods
  2.1 Data source
The National Health Insurance System (NHIS) in the Republic of 
Korea (ROK) began in 1963 and has been the single insurer of the entire 
population, currently about 52 million, since 2000. This study used data from 
the Health Insurance Review and Assessment Service (HIRA) database, which 
includes the claims data of the NHIS and National Medical Aid (NMA), 
which cover 97% and 3% of the entire population, respectively. The HIRA 
database includes all information regarding patient diagnosis (using the 
International Statistical Classification of Diseases and Related Health Problems 
10thr evision [ICD-10]codes),names of procedures, drug prescriptions, health 
insurance status (NHIS or NMA), types of medical institution visited, and 
health care costs.10 The HIRA database has been used in other research 
regarding hypertension11,12 and in a HIV adherence study.13 This database 
contains comprehensive data on the use of ART because, since 1989, all 
healthcare claims, including ART, are fully reimbursed when the condition 
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claimed for their use is relevant to HIV infection.
  2.2 Study population
We used the 2007–2016 HIRA databases to establish a cohort of 
incident HIV-infected individuals on initial ART (Figure 1). PLWH who 
received ART treatment at least once were defined as HIV-infected individuals, 
with an exclusion of those who were likely to have received ART for other 
preventive care and with a minimum of one year as the window period for 
defining incident cases. Eventually, 9283 incident HIV-infected individuals with 
initial ART prescription from 2008-2016 were recruited. After excluding 2790 
(30.0%) individuals with prevalent hypertension at cohort entry, 6493 were 
included as the final study population. A similar method of selecting 
HIV-infected individuals was used in another study.13 The numbers of 
prevalent or incident HIV-infected individuals on ART were compared to the 
official reports from the government. 
  2.3 Assessment of exposure and outcome definitions
Drug exposure was categorized into two groups (abacavir and 
non-abacavir ART), and the switch between the two were applied as a 
time-varying covariate on a daily basis. That is, the kind of ART (abacavir or 
non-abacavir ART) a participant received was assessed on a daily basis. When 
abacavir and non-abacavir ART were both prescribed for the same day, it was 
counted as abacavir exposure. The day of initial ART was the cohort entry 
day, and patients were followed until either incident hypertension diagnosis or 
the last day of study period (December 31, 2016). Hypertension was defined 
as at least two claims and also during more than 6 months of antihypertensive 
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treatment prescriptions. The choice for proper definition of outcome was 
explored in many ways in the sensitivity analysis. 
  2.4 Potential confounders
All comorbidities and co-medications were defined based on 
information prior to cohort entry. The following confounders related to the 
probability of prescribing abacavir instead of tenofovir were adjusted for: acute 
kidney failure, end stage renal disease (ESRD), osteoporosis, and history of 
switching between abacavir and non-abacavir ART. Acute kidney failure 
comprised kidney ischemia or infection, as well as temporary proteinuria, while 
ESRD included chronic kidney disease and dialysis or transplant related status. 
Factors related to hypertension, such as alcohol drinking, diabetes, 
dyslipidemia, atherosclerosis, history of medications, such as antidiabetic agent 
or statins, and prior history of exposure to protein inhibitors (PIs) or 
nucleoside analogue reverse transcriptase inhibitors (NRTIs) known to increase 
CVD risk were also adjusted for. An individual with AIDS was defined as 
one who received at least one diagnosis of an AIDS-defining illness, defined 
by the CDC.16 Requiring prophylactic antibiotics included having been 
prescribed a prophylactic dose of oral trimethoprim-sulfamethoxazole (80 
mg/400 mg: 1 tablet daily, 1 tablet twice daily, or 2 tablets daily) or oral 
dapsone (100 mg daily or 200 mg weekly). We assumed that individuals 
requiring prophylactic antibiotics had a CD4+ T-cell count <200 cells/µL, since 
PLWH must meet strict indication criteria that are supervised and supported by 
the government. PIs with known CVD risk included lopinavir, indinavir, and 
darunavir (including ritonavir boosted products)17; NRTIs with known CVD 
risk included didanosine, stavudine, and zidovudine.4,18 Adherence was 
examined using the medication possession ratio (MPR), calculated as the sum 
of days of treatment supplied for all ART prescriptions filled, from the first 
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ART fill date (the cohort entry date) until December 31, 2016, divided by the 
number of days in that same time period. NMA usage was considered a proxy  
for low socioeconomic status since they are considered to be the financially 
lowest 3% of the national population. Visiting medical institutions in 
metropolitan cities reflects better accessibility to healthcare, and the level of 
the institution reflects the level of medical care provided.
  2.5 Statistical analysis
The numbers of prevalent or incident HIV-infected individuals on 
ART were compared to the official reports from the government to evaluate 
the validity of cohort individuals. Demographic and clinical characteristics of 
patients with and without abacavir exposure were compared using Pearson’s χ2 
test for categorical variables. We calculated incidence rates of hypertension for 
abacavir users and non-abacavir ART users among the overall study population 
and among subgroups with known hypertension risk. Population attributable 
fraction (PAF) was calculated using the incidence rates, according to Levin’s 
formula: PAF reflects the proportion of disease in the population that can be 
attributed to a particular risk factor that, if eliminated, will potentially prevent 
the risk.19,20 Abacavir risk is presented in hazard ratios (HRs) and 95% 
confidence interval (CI) using Cox proportional hazards models adjusted for 
potential confounders mentioned above. An alpha of 0.05 was used for all the 
statistical hypothesis testing, and all statistical analyses were conducted using 
SAS Enterprise Guide, version 6.1 (SAS Institute, Inc., Cary, North Carolina, 
USA). This study was approved by the Institutional Review Board of Seoul 
National University College of Medicine (IRB No. E-1710-070-893), and the 
need for informed consent was waived by the board.
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  2.6 Sensitivity analysis
Two kinds of sensitivity analyses were conducted; 1) when choosing 
the definition of outcome after exploring the pattern of outcome occurrence, 
and 2) when comparing the results with matched subjects using propensity 
scores among those who never changed the exposure status, that is without 
switch. The first issue was whether or not to exclude early outcomes that 
occurred within 9 months after cohort entry. We compared the slope of 
outcome appearance using the cumulative distribution function (CDF) of 
follow-up days. CDF of a random variable X, evaluated at x, is the 
probability that X will take a value less than or equal to x. 
                          Fx(x)=P(X≤ x)
Therefore, CDF of follow-up days shows the probability of each follow-up day 
to end at that day, because follow-up day ends when outcome is detected. The 
second issue was the range of hypertension definition. We estimated 
hypertension risk when it was defined as same or more than two times and 
more than 6months of antihypertensive treatment prescriptions. We examined 
the number of outcomes as follow-up days pass by and made a choice based 
on scientific assumption considering the mechanism of hypertension.
After exploring the results of Cox Proportional Hazard (CPH) models, 
we limited the subjects into those without any switch between the two groups 
of abacavir and non-abacavir ART (reference), and matched the two groups 
using propensity scores. The balance was confirmed using standardized 
differences, and those with <0.1 were considered as well matched as suggested 
by Austin. The HRs before and after two different subjects were compared 
and one was chosen based on adequate interpretation of the results.
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3. Results
Of the 11944 nationwide HIV-infected individuals from the years 
2007-2016, 6493 incident ART users without hypertension before cohort entry 
(initial ART) from 2008-2016 were selected as the final study participants 
(Figure 1). 
  3.1 Cohort compared to the KCDC reports
The number of prevalent HIV-infected individuals detected from the 
claims database was about 1,000 less than the number of cumulative number 
of the infected reported from the KCDC (Table 1). However, the difference 
showed a steady decrease each year. The number of incident HIV-infected 
individuals was similar with that of the KCDC reports (Table 2). Higher 
numbers of individuals were detected from the claims cohort in recent years.
Figure 1. Selection of the study population. 
ART, antiretroviral treatment; NRTI, nucleoside analogue reverse transcriptase 
inhibitors; PEP, post-exposure prophylaxis.
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　 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 
Domestic individuals (KCDC) 4,337 5,030 5,666 6,290 7,030 7,788 8,662 9,615 10,502 11,439 
Foreigners (KCDC) 648 751 822 886 957 1,042 1,143 1,253 1,387 1,524 
Domestic+Foreigners (KCDC) 4,985 5,781 6,488 7,176 7,987 8,830 9,805 10,868 11,889 12,963 
Cohort from the claims database 2,661 3,256 3,879 4,599 5,404 6,220 7,123 8,222 9,276 10,413 
KCDC Total - Cohort 2,324 1,774 1,787 1,691 1,626 1,568 1,539 1,393 1,226 1,026 
KCDC Domentic - Cohort 1,676 1,774 1,787 1,691 1,626 1,568 1,539 1,393 1,226 1,026 
　 2008 2009 2010 2011 2012 2013 2014 2015 2016 
Domestic individuals (KCDC) 797 768 773 888 868 1,013 1,081 1,018 1,062 
Domestic+Foreigners (KCDC) 900 839 837 959 953 1,114 1,191 1,152 1,199 
Cohort from the claims database 798 781 863 963 977 1,097 1,248 1,236 1,320 
Cohort - KCDC Total -102 -58 26 4 24 -17 57 84 121 
Table 1. The Number of Prevalent HIV-Infected Individuals in the Cohort Compared to the KCDC Reports
Table 2. The Number of Incident HIV-Infected Individuals in the Cohort Compared to the KCDC Reports
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  3.2 Main results of CPH models
Among the final study population, 3144 (48.4%) had been exposed to 
abacavir at least once, while 3349 (51.6%) had never received abacavir (Table 
3). Among the total study population, 1173 (18.1%) changed at least once 
from abacavir to non-abacavir and 1593 (24.5%) vice versa. A total of 6493 
participants were followed-up for 24072 person-years (PY), while 1599 (24.6%) 
developed incident hypertension during follow up from 2008 to 2016. 
However, after exclusion of outcomes within 9 months after the cohort entry 
from 646 individuals, 953 (14.7%) events occurred, resulting in incidence rates 
of 4.6, 3.6, and 4.0 per 100 PY among abacavir users, non-abacavir ART 
users, and the total HIV-infected individuals on ART, respectively (Table 4). 
PAF of abacavir on hypertension was calculated as 12%. Even though 
abacavir seemed to increase hypertension risk before adjustment, it lost 
statistical significance after adjustment. However, poor ART adherence and 
requiring prophylactic antibiotics were statistically significant factors in the 
association between abacavir and hypertension (HR ranged from 1.1 to 1.9, 
Table 4) 
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N % N % N %
Total 6,493 3,144 48.4 3,349 51.6 
Gender
  Men 6,018 92.7 2,920 92.9 3,098 92.5 0.6
  Women 475 7.3 224 7.1 251 7.5 
Age 0 
  <20 206 3.2 82 2.6 124 3.7 <.0001
  20-29 1,825 28.1 797 25.3 1,028 30.7 
  30-39 1,888 29.1 923 29.4 965 28.8 
  40-49 1,569 24.2 835 26.6 734 21.9 
  ≥50 1,005 15.5 507 16.1 498 14.9 
Comorbidity  prior to cohort entry
  Acute kidney  
  failure 442 6.8 211 6.7 231 6.9 0.8
  AIDS defining illness 1,114 17.2 547 17.4 567 16.9 0.6
  Alcohol 400 6.2 187 5.9 213 6.4 0.5
  Cancer 478 7.4 236 7.5 242 7.2 0.7
  COPD 1,011 15.6 469 14.9 542 16.2 0.2
  Diabetes mellitus 919 14.2 412 13.1 507 15.1 0.02
  Dyslipidemia 2,646 40.8 1,159 36.9 1,487 44.4 <.0001
  End stage renal disease 36 0.6 26 0.8 10 0.3 0.004
  Hepatitis B infection 354 5.5 143 4.5 211 6.3 0.002
  Hepatitis C infection 542 8.3 255 8.1 287 8.6 0.5
  Osteoporosis 338 5.2 156 5.0 182 5.4 0.4
  Prior hospitalization 3,135 48.3 1,471 46.8 1,664 49.7 0.02
  Psychiatric disorders 2,128 32.8 1,012 32.2 1,116 33.3 0.3
Medications  prior to cohort entry
  Antidiabetic agents 184 2.8 101 3.2 83 2.5 0.09
Table 3. Characteristics of Incident HIV-infected Individuals on Antiretroviral 
Treatment during 2008-2016
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  Statins 131 2.0 66 2.1 65 1.9 0.7
ART  adherence by MPR (%) 0 
  95 ≤ MPR 4,414 68.0 2,087 66.4 2,327 69.5 <.0001
  80 ≤ MPR < 95 681 10.5 384 12.2 297 8.9 
  50 ≤ MPR < 80 569 8.8 314 10.0 255 7.6 
  MPR < 50 829 12.8 359 11.4 470 14.0 
Requiring  prophylactic 
  antibiotics
38.0 1,340 42.6 1,130 33.7 <.0001
ART  initiation (Year of cohort entry)
  2008 679 10.5 432 13.7 247 7.4 <.0001
  2009 623 9.6 398 12.7 225 6.7 
  2010 631 9.7 449 14.3 182 5.4 
  2011 661 10.2 489 15.6 172 5.1 
  2012 659 10.1 349 11.1 310 9.3 
  2013 737 11.4 269 8.6 468 14.0 
  2014 834 12.8 193 6.1 641 19.1 
  2015 816 12.6 158 5.0 658 19.6 
  2016 853 13.1 407 12.9 446 13.3 
Type  of medical institution
  Tertiary hospitals 4,435 68.3 2,144 68.2 2,291 68.4 0.9
  Others 2,058 31.7 1,000 31.8 1,058 31.6 
Region  of medical institution
  Seoul (capital city) 3,275 50.4 1,674 53.2 1,601 47.8 <.0001
  Metropolitan cities 1,718 26.5 831 26.4 887 26.5 
  Rural 1,500 23.1 639 20.3 861 25.7 
Health  Insurance status 0 
  National health insurance 6,030 92.9 2,887 91.8 3,143 93.8 0.002
  Medical aid 463 7.1 257 8.2 206 6.2 
ABC, abacavir; AIDS, acquired immuno-deficiency syndrome; ART, antiretroviral 
treatment; CI, confidence interval; COPD, chronic obstructive pulmonary disease; 
MPR, medication possession ratio
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　 Abacavir Non-abacavir ART Hazard ratio (95% CI) 　
　 Events PY IR Events PY IR Unadjusted 95% CI Adjusteda 95% CI p-value
Overall 397 8720 4.6 556 15352 3.6 1.1 1.0-1.3 1.2 1.0-1.4 0.061 
ART adherence by MPR (%)
  95 ≤ MPR 239 6050 4.0 348 10360 3.4 1(ref) 1(ref)
  80 ≤ MPR < 95 70 1353 5.2 72 2179 3.3 1.1 0.9-1.4 1.1 0.9-1.3 0.294
  50 ≤ MPR < 80 56 896 6.3 78 1773 4.4 1.4* 1.2-1.7 1.4* 1.1-1.7 0.0009
  MPR < 50 34 421 8.1 57 1039 5.5 1.8** 1.4-2.3 1.9** 1.5-2.4 <0.0001
Requiring prophylactic  
  antibioticsb
193 3834 5.0 278 6392 4.3 1.3 1.2-1.5 1.2* 1.0-1.3 0.023
Table 4. Hypertension Risk of Abacavir compared to Non-abacavir ART among Overall Study Population 
ART, antiretroviral treatment; CI, confidence interval; IR, incidence rate per 100 PY; MPR, medication possession ratio; PY, person-years
a Adjusted for gender, age group, antiretroviral treatment adherence, cohort entry year, CD4+ T-cell count < 200 cells/µL (yes/no), switch 
between abacavir and non-abacavir (yes/no), type and region of medical institution, financial status, prior history of the following: acute kidney 
disease, AIDS-defining illness, atherosclerosis, alcohol, cancer, COPD, diabetes, dyslipidemia, ESRD, hepatitis B infection, hepatitis C infection, 
osteoporosis, psychiatric disease, hospital admission, antidiabetic agent use, statin use, prescription of other ART of known cardiovascular risk, 
the year of ART initiation. b A proxy for CD4+ T-cell count < 200 cells/µL * p-value <0.05 ** p-value <0.001
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a. When early outcomes within 9 months of cohort entry was not excluded
a1. Hypertension
    : 1≤diagnosis or 1≤prescription
a2. Hypertension: 2≤prescriptions
b. When early outcomes within 9 months of cohort entry was excluded
b1. Hypertension
    =1≤diagnosis or 1≤prescription
b2. Hypertension: 2≤prescriptions
3.3 Sensitivity analysis results by outcome
In order to explore the validity of outcome definition and whether or 
not to exclude early outcomes, we compared the CDF of follow-up days, 
examined the number of outcomes, and compared the risk of hypertension 
using different definition.




    =1≤diagnosis or 1≤prescription
a2. Hypertension: 2≤prescriptions
(When early outcomes within 9 
months of cohort entry was 
excluded)
(When early outcomes within 9 
months of cohort entry was not
excluded)
Figure 3. Comparison of number of outcomes by follow-up days
The total number of outcomes varied with different definitions of 
hypertension as the following: 1021 outcomes when the definition was 1≤
diagnosis or 1≤prescription of antihypertensive treatments excluding outcomes 
within 9 months of cohort entry, 838 outcomes when the definition was 2≤
prescriptions without excluding any outcome, and 631 outcomes when the 
definition was narrower as initial 2≤prescriptions within 6 months. In case of 
1021 outcomes, 397 occurred during abacavir treatment, 556 during 
non-abacavir ART treatment, and 68 without any ART treatment.
The CDF showed two different patterns of outcome appearance: 1) 
early risk within 3 to 30 months of follow-up days, and 2) a steadily 
increasing risk (Figure 2), of which we considered that the latter is a more 
explainable mechanism for hypertension. The number of outcomes according to 
follow-up days also varied between the two kinds of definitions (Figure 3). 
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  3.4 Sensitivity analysis results by subject
The higher risk of hypertension induced by abacavir among 
those with poor adherence found at the main analysis was difficult to 
interpretate, since it is clear that there is no preventive effect of 
abacavir in inducing hypertension. Therefore we limited subjects with a 
more strict criteria and compared the results with the main ones.
First, among the 6093 incident HIV-infected individuals, 1758 
(27%) had been switched between the exposure and reference group, 
and 4735 (73%) had not. However, since exposure is considered as a 
time-varing covariate, those with switch history between the exposure 
and reference group may interfere propensity score matching. Therefore, 
we limited the study population into those without any switch and 
performed matching resulting in 1234 study population (Table 5). 
However, after limiting study population and matching using 
propensity scores, higher risk of hypertension induced by abacavir  
among the poor adherence groups was not found (Table 6). There was 
marginally significant risk of hypertension induced by abacavir (HR 1.7, 
1.0-3.0). Since there was a higher risk among those diagnosed with HIV 
infection after the year 2013, we performed survival analysis stratified 
by the year of diagnosis before and after 2013 (Table 7).
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　　 N % N % N % N %
Total 639 4,096 617 617
Gender
  Men 602 0.94 3,800 0.93 0.06 580 0.94 580 0.94 0.00 
  Women 37 0.06 296 0.07 -0.06 37 0.06 37 0.06 0.00 
Age (mean, SD) 36 11.9 37 11.6 0.03 36 11.9 37 11.6 0.03 
Comorbidity prior to cohort entry
  Acute kidney failure 78 0.12 264 0.06 0.20 67 0.11 60 0.10 0.09 
  AIDS defining illness 99 0.15 677 0.17 -0.03 98 0.16 102 0.17 -0.02 
  Alcohol 44 0.07 259 0.06 0.02 41 0.07 38 0.06 0.02 
  Cancer 45 0.07 292 0.07 0.00 45 0.07 48 0.08 -0.02 
  COPD 97 0.15 643 0.16 -0.01 93 0.15 93 0.15 0.00 
  Diabetes mellitus 85 0.13 609 0.15 -0.05 84 0.14 90 0.15 -0.03 
  Dyslipidemia 307 0.48 1,723 0.42 0.12 290 0.47 283 0.46 0.02 
Table 5. Study Subjects Before and After Propensity Score Matching among HIV-Infected Individuals without Switch
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  End stage renal disease 7 0.01 17 0.00 0.08 5 0.01 5 0.01 0.00 
  Hepatitis B infection 24 0.04 245 0.06 -0.10 24 0.04 22 0.04 0.02 
  Hepatitis C infection 51 0.08 329 0.08 0.00 50 0.08 48 0.08 0.01 
  Osteoporosis 71 0.11 205 0.05 0.23 48 0.08 52 0.08 -0.02 
  Prior hospitalization 338 0.53 1,961 0.48 0.10 327 0.53 298 0.48 0.09 
  Psychiatric disorders 220 0.34 1,336 0.33 0.04 207 0.34 190 0.31 0.06 
Medications prior to cohort entry
  Antidiabetic agents 21 0.03 109 0.03 0.04 21 0.03 13 0.02 0.08 
  Statins 22 0.03 80 0.02 0.09 21 0.03 12 0.02 0.09 
ART adherence (MPR (mean,SD)) 92 21.0 87 25.7 -0.20 91 22.5 89 24.5 -0.09 
Requiring prophylactic antibiotics 177 0.28 1,505 0.37 -0.19 176 0.29 181 0.29 -0.02 
ART initiation (Year of cohort entry)
  2008 27 0.04 374 0.09 -0.20 27 0.04 26 0.04 0.01 
  2009 28 0.04 378 0.09 -0.19 28 0.05 39 0.06 -0.08 
  2010 35 0.05 332 0.08 -0.10 34 0.06 29 0.05 0.04 
  2011 60 0.09 340 0.08 0.04 60 0.10 60 0.10 0.00 
  2012 65 0.10 400 0.10 0.01 65 0.11 62 0.10 0.02 
  2013 51 0.08 508 0.12 -0.15 51 0.08 52 0.08 -0.01 
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  2014 30 0.05 679 0.17 -0.39 30 0.05 30 0.05 0.00 
  2015 42 0.07 671 0.16 -0.31 42 0.07 36 0.06 0.04 
  2016 301 0.47 414 0.10 0.90 280 0.45 283 0.46 -0.01 
Type of medical institution
  Tertiary hospitals 399 0.62 2,802 0.68 -0.13 397 0.64 405 0.66 -0.03 
  Others 240 0.38 1,294 0.32 0.13 220 0.36 212 0.34 0.03 
Region of medical institution
  Metropolitan cities 504 0.79 3,103 0.76 0.07 482 0.78 501 0.81 -0.08 
  Rural 135 0.21 993 0.24 -0.07 135 0.22 116 0.19 0.08 
Health Insurance status
  National health insurance 593 0.93 3,829 0.93 -0.03 571 0.93 581 0.94 -0.07 
  Medical aid 46 0.07 267 0.07 0.03 46 0.07 36 0.06 0.07 
Ever received NRTI of known CVD riskª 28 0.04 1,235 0.30 -0.73 28 0.05 29 0.05 -0.01 
Ever received PI of known CVD riskb 139 0.22 1,413 0.34 -0.29 138 0.22 125 0.20 0.05 
AIDS, acquired immuno-deficiency syndrome; ART, antiretroviral treatment; COPD, chronic obstructive pulmonary disease; MPR, medication 
possession ratio;
ª Didanosine, stavudine, and zidovudine
b Lopinavir, indinavir, and darunavir including ritonavir boosted products 
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Before matching After matching
　 HR 95% CI p HR 95% CI p
Overall 1.1 0.8-1.3 0.6 1.7 1.0-3.0 0.06
Gender
  Women 1(ref) 1(ref)
  Men 1 0.7-1.4 0.9 1.5 0.6-3.8 0.4
Age
  <30 1(ref) 1(ref)
  30≤ 2 1.6-2.6 <0.0001 2.3 1.4-3.1 0.05
Type of medical institution
  Tirtiary hospital 1(ref) 1(ref)
  Others 1 0.9-1.3 0.6 1.2 0.8-1.8 0.5
Region of medical institution
  Seoul (capital city) 1(ref) 1(ref)
  Metropolitan cities 1.2 0.9-1.4 0.2 1.1 0.7-1.8 0.7
  Rural 1.1 0.9-1.4 0.4 1.4 0.8-2.3 0.3
Health Insurance status
  National health insurance 1(ref) 1(ref)
  Medical aid 1 0.7-1.3 0.8 0.6 0.3-1.3 0.2
Comorbidity prior to cohort entry
  Acute kidney failure 1 0.6-1.4 0.7 0.6 0.2-1.5 0.3
  Alcohol 0.9 0.6-1.3 0.5 1 0.5-2.0 1
  Cancer 1.3 1.0-1.8 0.1 1.7 0.9-3.0 0.1
  Cardiovascular disease 1.8 1.0-3.0 0.04 1.2 0.4-4.1 0.8
  COPD 1.2 0.9-1.5 0.2 1.4 0.9-2.4 0.2
Table 6. Hypertension Risk of Abacavir Compared to Non-Abacavir ART 
among HIV-Infected Individuals without Switch
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  Diabetes mellitus 1 0.7-1.3 0.9 0.7 0.3-1.4 0.3
  Dyslipidemia 1.2 0.9-1.4 0.2 1 0.6-1.5 0.9
  Hepatitis B infection 1.6 1.2-2.2 0.002 2.3 1 0.1
  Hepatitis C infection 0.8 0.5-1.1 0.1 1.2 0.6-2.5 0.5
  Osteoporosis 0.7 0.4-1.3 0.2 0.6 0.2-2.1 0.4
  Prior hospitalization 0.9 0.7-1.0 0.1 0.9 0.6-1.4 0.6
  Psychiatric disorders 1.2 1.0-1.4 0.1 1.8 1.0-2.5 0.06
  Medications prior to cohort entry
  Antidiabetic agents 1.6 1.0-2.4 0.04 2.1 0.8-5.4 0.1
  Statins 1.9 1.2-3.0 0.005 2 0.7-5.3 0.2
ART adherence (MPR)
  80≤MPR 1(ref) 1(ref)
  MPR < 80 1.2 1.0-1.4 0.1 1.7 0.8-2.6 0.2
AIDS defining illness 1.02 0.8-1.2 1 1.1 0.6-1.7 0.8
Requiring prophylactic antibiotics 1.28 1.1-1.5 0.002 1 0.6-1.5 0.9
ART initiation (Year of cohort entry)
  < 2013 1(ref) 1(ref)
  2013≤ 1.6 1.2-2.1 0.003 2.9 1.1-3.0 0.05
Ever received NRTI of known 
CVD riskª
0.7 0.6-0.9 0.01 1 0.5-2.0 1
Ever received PI of known 
CVD riskb 1 0.8-1.2 1 1.3 0.8-1.9 0.3
AIDS, acquired immuno-deficiency syndrome; ART, antiretroviral treatment; COPD, 
chronic obstructive pulmonary disease; MPR, medication possession ratio;
ª Didanosine, stavudine, and zidovudine
b Lopinavir, indinavir, and darunavir including ritonavir boosted products 
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　 < 2013 2013≤ 
　 HR 95% CI p HR 95% CI p
Overall 1.0 0.4-2.3 0.9 3.1 1.3-7.2 0.01
ART  adherence (MPR)
  80 ≤ MPR 1(ref) 1(ref)
  MPR < 80 1.5 0.4-5.1 0.5 2.3 0.9-3.1 0.07
Age
  <30 1(ref) 1(ref)
  30≤ 3.8 1.2-11.7 0.02 2.1 1.1-4.2 0.04
Comorbidity  prior to cohort entry
  Cancer 2.5 1.2-5.2 0.01
  COPD 1.9 1.0-3.5 0.05
  Psychiatric disorders 1.9 1.2-3.1 0.01
Medications  prior to cohort entry
  Antidiabetic agents 　 　 　 3.8 1.2-11.5 0.02
Table 7. Hypertension Risk of Abacavir Compared to Non-Abacavir ART among HIV-Infected Individuals without Switch 
Stratified by the Year of Diagnosis
COPD, chronic obstructive pulmonary disease; MPR, medication possession ratio
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4. Discussion
The number of HIV-infected individuals detected from the HIRA 
claims database was similar with that of the government reports. The higher 
numbers of incident patients of the claims cohort reflects the clinical trend of 
receiving ART as early as one is diagnosed in recent days. 
In this nationwide cohort of incident HIV-infected individuals on 
initial ART from 2008 to 2016, the incidence rates of hypertension were 4.6 
per 100 PY among abacavir users and 3.6 per 100 PY for non-abacavir users. 
User of abacavir showed a higher risk of hypertension than non-abacavir ART 
users only in some subgroups. The incidence rate of hypertension from this 
study is comparable with the 4.6 per 100 PY reported among the general 
population, calculated from a study in the ROK.21 The incidence rate of 
hypertension among ART users from this study may be interpreted as higher 
than the general population because the cohort of HIV-infected individuals was 
a much younger group of people; individuals aged ≥50 years made up only 
16% of the cohort, compared to 53% among the general population in 2017. 
However, the incidence rate in this study was higher than those from North 
American cohorts: 2.6 per 100 PY overall, 2.2 per 100 PY for non-Blacks, 
and 3.3 per 100 PY for Blacks among HIV-infected individuals on ART15 
and 3.4 per 100 PY among heterogeneous PLWH including about 59% of 
Blacks and 90% on ART.22 Racial disparities in the occurrence of hypertension 
among PLWH was shown in other studies,15,22 as well as among the general 
population.23
Even though the main analysis of the CPH model revealed a similar 
risk factors as found in other studies such as old age24,25 and being male25, the 
higher risk among the poor adherence group questioned the validity of the 
model. Those with a more strict definition of which were HIV-infected 
individuals without any switch revealed a more interpretable results on the risk 
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of abacavir. Even though, propensity score matching thereafter decreased the 
number of subjects from 6093 to 1234, the results seemed to be more 
explainable. Therefore, not only there was a bias toward the null hypothesis 
resulting from the switch between the exposure and reference group, but also 
the validity of the CPH model could have been affected.
Among those after matching, abacavir elavated the risk of hypertension 
with a marginal significance, and those aged same or over 30’s, those with 
psychiatric disease history, and those diagnosed with HIV infection after the 
year 2013 were risk factors in this association. However, when stratified by 
the year of diagnosis, recently diagnosed individuals had higher adherence (80≤
MPR 93.0% vs 77.2%), higher proportion of aged<30 (43.2% vs 25.3%), and 
higher proportion of those with psychiatric disease history (34.1% vs 28.6%). 
These people who often visited clinics for ART could have been diagnosed 
with hypertension more than the control group (detection bias). Also, since 
there were reports such as NEJM Journal Watch giving alert about CVD risk 
of abacavir, which continued until recently, those prescribed with abacavir 
could have been monitored with blood pressure more often than the control 
group (differential ascertainment detection bias). However, while the risk of 
abacavir is assumed to be based on inflammation, since those with good 
adherence must have less effect of inflammation rooting from HIV infection 
itself, the risk of abacavir found among those with good adherence might not 
be explained only by biases. Therefore, those with good adherence should be 
monitored with blood pressure when prescribed with abacavir.
PAF was calculated in this study and was 12%. This indicates that, 
among a variety of risk factors affecting hypertension, about 12% of incident 
cases occurred as the result of abacavir in HIV-infected individuals on ART. 
The size of the PAF is comparable with the PAFs for diabetes or high 
cholesterol (both, 13%) in the USA.26
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Sensitivity analyses were done by the definition of outcome and the 
study subjects. Up to now, the biological mechanism of abacavir effect on 
hypertension (or CVD) is still unknown. After exploring the pattern of 
outcomes, we assumed that increase in blood pressure must take a constant 
slope of appearance. Actually, in case of CVD risk of abacavir, the issue in 
many of the studies was ‘when’ the risk became maximized. While some 
studies only reported recent (within 6 months) exposure as being a risk,4,14,37
other studies reported this risk to be high after 3 years,33,38 and in another 
study, the risk peaked after 13-24 months of exposure.32 However, in case of 
hypertension we expected hypertension as a steady progress of physiologic 
change.
This study has strengths in its study design. First, it used approaches 
to take into account for immortal time bias36: time-dependent definition for the 
drug exposure and initial ART use requirement for the study population. This 
study treated drug exposure as a time-varying covariate measured in a daily 
unit to precisely reflect exposure, and it included incident HIV-infected 
individuals who were all starting their initial ART from a nationwide cohort, 
which provides high homogeneity and decreases survival bias. Second, we 
decided to evaluate the risk of long term exposure of hypertension risk to 
reflect current situations in the real world where PLWH are not being 
recommended to change abacavir after a certain period of use. Therefore, 
PLWH on abacavir for many years were our main interest to ensure that the 
results can be generalized to those on abacavir for as long as 9 years. It was 
suggested that the duration of ART treatment may modify the association 
between ART and hypertension among PLWH.3 In addition, the study period 
was as long as 9 years and included the era of new combination ART agents 
in the market. In ROK, tenofovir/ emtricitabine/ elvitegravir/ cobicistat (TDF/ 
FTC/ EVG/ c) was released in 2014 and abacavir/ lamivudine/ dolutegravir 
(ABC/ 3TC/ DTG) in 2015. Third, in seeking causal inference concerning the 
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detrimental effect of abacavir, confounding by indication and channeling bias is 
particularly important, because switching of drugs is common. For example, 
the alternate treatment of choice for abacavir, tenofovir, is avoided in patients 
with poor renal conditions39; after the 2008 D:A:D publication, abacavir was 
avoided in patients with CVD risk.34 During the study period, patients who 
received abacavir as their initial ART were 897 (13.8%), and 2056 (31.7%) 
had changed ART between abacavir and non-abacavir ART with a maximum 
of 21 switching times. Therefore, we included a number of potential 
confounders that may affect treatment choice or outcomes. Potential 
confounders were defined based on the information before cohort entry in 
order to overcome reverse causation. In case of comorbidities, not only the 
primary diagnosis but all the other reasons for clinical visits were included. 
Our study has several limitations including the use of administrative 
database without information on smoking status or glomerular filtration rate 
(GFR). However, GFR did not seem to influence the association between 
abacavir exposure and CVD risk in a previous study14. However, we included 
the history of acute kidney failure and ESRD prior to cohort entry in order to 
adjust for renal function and chronic obstructive pulmonary disease in order to 
adjust for smoking status using diagnostic codes that were strictly supervised 
by the government for reimbursement. Also, in selecting the study population, 
an arbitrary time of one year was used to identify incident PLWH on initial 
ART. Therefore, some HIV-infected individuals who never visited any medical 
institution could have been excluded. However, the number of yearly incident 
HIV-infected individuals selected in our cohort was similar to the number 
reported in an official government report.40 In addition, in order to evaluate 
the potential population impact using PAF, there should be a causal 
relationship between the exposure and the outcome. However, as of yet, the 
mechanism between abacavir and hypertension remains unclear. Also, abacavir 
is not such an exposure that could be eliminated for the entire exposure 
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group. Nevertheless, PAF enabled the evaluation of the quantitative risk of 
abacavir.
5. Conclusion
In conclusion, the similar numbers between the KCDC reports and this 
cohort constructed from the HIRA claims database highly suggests the 
possibility of further application of this database, while there is no such data 
regarding HIV-infected individuals in Korea. Considering a PAF of 12%, 
abacavir use should be followed by regular monitoring on blood pressure, 
especially among those with good ART adherence. Even though this study 
could not show a concrete result on the risk of hypertension of abacavir due 
to lack of statistical power, we showed the importance in arbitrary definitions 
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배경 : 항레트로바이러스제(ART)인 아바카비어는 심혈관계질환의 발생위험
과 연관성이 제기된 바 있으나 고혈압과의 연관성은 연구된 적이 없다.
목적 : HIV 감염인 연구를 건강보험청구자료를 활용하여 수행하며, 감염인
의 고혈압 발생률과 아바카바이어로 인한 고혈압 발생위험을 평가한다.
방법 : 2007-2016년 국민건강심사평가원의 청구자료를 이용하여 HIV 감염
자 코호트를 구축하였다. 전 국민 코호트에서 6,493명의 코호트 입적 당시 
고혈압이 없었던 신규 감염된 HIV감염자를 대상으로 고혈압의 발생률을 
추정하고, 이를 통해 Population attributable fraction(PAF)을 산출하였다.
이 연구대상 전체와 노출군과 대조군 간 약물 변경이 없는 감염인만 대상
으로 제한한 후 propensity score (PS) matching을 한 1,234명을 대상으로 
Cox proportional hazard model을 이용하여 abacavir 약제로 인한 고혈압 
발생위험을 교란변수를 보정한 hazard ratio(HR)와 95%신뢰구간(CI)을 산
출하였다. ART 처방은 하루 단위의 time-varying covariate로 적용하여 시
간에 따라 처방여부가 변하는 것을 반영하였다.
결과: 청구자료를 이용한 HIV 감염인 코호트는 질병관리본부에 신고된 감
염인 숫자와 크게 다르지 않았다. 아바카비어 처방자와 비처방자(다른 
ART 처방자)의 고혈압 발생률은 각각 100인년 당 4.6과 3.6이었고, 이로부
터 PAF은 12로 산출되었다. 약제변경없는군 내에서 PS matching된 대상에
서 아바카비어 노출은 고혈압 발생의 위험을 높이는 것으로 나타났으나 통
계적으로 경계성 유의성을 보였다(HR 1.7 [95%CI, 1.0-3.0], P value, 0.06).
이 연관성에 30대 이상의 연령, 정신과 질환의 병력, 2013년 이후 진단 이
력은 유의하게 영향을 미치는 인자로 나타났다.
결론 : 건강보험청구자료를 이용하여 HIV 감염인에 대한 역학연구가 가능
한 자료원 구축을 통해 향후 이 자료원의 활용가치가 크다. 아바카비어 약
제 처방 시 혈압에 대한 모니터링이 필요하며, ART 순응도가 높은 최근 
진단자에서 특히 그러하다.
주요어 : 고혈압; 아바카비어; 인간면역결핍바이러스; 레트로바이러스제;
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